Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

C S J Probert, S D Hearing, S Schreiber, T Kühbacher, S Ghosh, I D R Arnott, A Forbes

Research output: Contribution to journalArticlepeer-review

343 Citations (Scopus)


Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.
Original languageEnglish
Pages (from-to)998-1002
Number of pages5
Issue number7
Publication statusPublished - Jul 2003


  • Adult
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • C-Reactive Protein
  • Colitis, Ulcerative
  • Double-Blind Method
  • Drug Resistance
  • Female
  • Glucocorticoids
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Quality of Life
  • Remission Induction
  • Treatment Outcome

Cite this